이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Noxopharm 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Gisela Mautner

최고 경영자

AU$491.6k

총 보상

CEO 급여 비율	83.4%
CEO 임기	2.7yrs
CEO 소유권	n/a
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04

CEO 보상 분석

Gisela Mautner 의 보수는 Noxopharm 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-AU$4m
Mar 31 2024	n/a	n/a	-AU$8m
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$492k	AU$410k	-AU$15m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$1m	AU$201k	-AU$19m

보상 대 시장: Gisela 의 총 보상 ($USD 331.09K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 300.79K ).

보상과 수익: Gisela 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gisela Mautner

2.7yrs

테뉴어

AU$491,562

보상

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gisela Mautner	CEO, Executive MD & Director	2.7yrs	AU$491.56k	데이터 없음
Shawn Van Boheemen	Chief Financial Officer	5.5yrs	데이터 없음	데이터 없음
Jeanette Bell	Chief Operating Officer	4.8yrs	데이터 없음	데이터 없음
John Wilkinson	Chief Scientific Officer of Oncology	2.8yrs	데이터 없음	데이터 없음
Olivier Laczka	Chief Scientific Officer of Inflammation	2.8yrs	데이터 없음	데이터 없음
David Franks	Company Secretary	7.8yrs	AU$16.49k	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 관리: NOX 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gisela Mautner	CEO, Executive MD & Director	no data	AU$491.56k	데이터 없음
Frederick Bart	Non-Executive Chairman	4.4yrs	AU$45.00k	2.57% A$ 900.9k
Peter Marks	Non-Executive Deputy Chairman	8.6yrs	AU$60.00k	0.31% A$ 108.0k
Boris Patkin	Non-Executive Director	4.6yrs	AU$56.69k	0.22% A$ 75.6k

4.6yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: NOX 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Noxopharm 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Non-Executive Chairman recently bought AU$50k worth of stock

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Recent updates

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Founder exercised options to buy AU$5.5m worth of stock.

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.69

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령